Sponsor pipeline

Jonathan Brammer clinical trial pipeline

Get alerts when Jonathan Brammer's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-10-16

What changed in the last 30 days

1 trial changed in the last 30 days: 0 stopped, 1 with a notable change, 0 with minor changes only.

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Active trials by phase

Phase 1/2
1
Phase 2
2

Active trials

NCT IDTitleConditionStatusUpdated
Phase 2
NCT05592015 Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia T-Cell Large Granular Lymphocyte Leukemia Recruiting 2026-10-01
NCT07356245 Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma T-cell Lymphoma Recruiting 2026-04-15
Phase 1/2
NCT05141682 Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular… T-Cell Large Granular Lymphocyte Leukemia Active, Not Recruiting 2026-07-28

Disease areas by active trials

Leukemia (3) · Acute Lymphoblastic Leukemia (ALL) (1) · Non-Hodgkin Lymphoma (1)

Get alerts when Jonathan Brammer's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free